Baker Bros. Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Baker Bros. Advisors’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-55,294	Closed	-$709K	–	125
2022 Q2	$709K	Sell	55,294 -236,507	-81%	-$3.28M	﹤0.01%	103
2022 Q1	$4.45M	Hold	291,801	–	–	0.03%	88
2021 Q4	$5.17M	Hold	291,801	–	–	0.03%	93
2021 Q3	$6.13M	Hold	291,801	–	–	0.03%	88
2021 Q2	$5.75M	Hold	291,801	–	–	0.03%	93
2021 Q1	$8.48M	Buy	291,801 +185,185	+174%	+$5.18M	0.04%	81
2020 Q4	$3.23M	Sell	106,616 -11,484	-10%	-$251K	0.01%	103
2020 Q3	$1.88M	Sell	118,100 -6,300	-5%	-$115K	0.01%	103
2020 Q2	$2.46M	Sell	124,400 -125,600	-50%	-$2.4M	0.01%	97
2020 Q1	$3.08M	Hold	250,000	–	–	0.02%	78
2019 Q4	$4.62M	Hold	250,000	–	–	0.02%	72
2019 Q3	$3.46M	Hold	250,000	–	–	0.02%	72
2019 Q2	$3.66M	Buy	+250,000	New	+$3.66M	0.02%	68

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Baker Bros. Advisors's NGM Position: Q3 2022 in Review

Baker Bros. Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2022, closing a stake of 55,294 shares — an estimated $709K sold.

Baker Bros. Advisors first reported a position in NGM in Q2 2019 and held it in 13 quarters. The position peaked at $8.48M in Q1 2021. 128 funds tracked by Wall St. Rank hold NGM as of Q3 2022.

Baker Bros. Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Baker Bros. Advisors sold 55,294 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $709K.
Baker Bros. Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
Baker Bros. Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $8.48M in Q1 2021.
128 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.